iShares Nasdaq BioTech ETF (IBB-Q) Stock Predictions - Stockchase
WATCH LIST
57
iShares Nasdaq BioTech ETF (IBB-Q)

ON STOCKCHASE SINCE Nov 2001

E.T.F.'s

iShares Nasdaq BioTech ET...

IBB-Q

16 watching          
Join the Discussion

iShares Nasdaq BioTech ETF (IBB-Q) SAVE Apr, 19, 2019, 8:01 am

104.54 0.6 (0.57%)

What the experts are saying about IBB-Q



  • All
  • Filtered
Signal Opinion Expert
TOP PICK
He believes in U.S. biotech which is mostly this ETF (and 10% pharma, plus life sciences). Considering the backdrop of an aging population.
E.T.F.'s
0 0 0 0 0
0 comments
He believes in U.S. biotech which is mostly this ETF (and 10% pharma, plus life sciences). Considering the backdrop of an aging population.
E.T.F.'s
0 0 0 0 0
0 comments
David Cockfield

Managing D, Northland Wealth Man...

Price Price
$104.540
Owned Owned
Yes

PAST TOP PICK
(A Top Pick Feb 02/18, Down 3%) Not a bad return given the markets we've had over the last year.
E.T.F.'s
0 0 0 0 0
0 comments
(A Top Pick Feb 02/18, Down 3%) Not a bad return given the markets we've had over the last year.
E.T.F.'s
0 0 0 0 0
0 comments
David Cockfield

Managing D, Northland Wealth Man...

Price Price
$109.140
Owned Owned
Yes

PAST TOP PICK

(A Top Pick Nov. 17/17, Up 7%)  There was a three for one stock split.  This and healthcare are in a long term secular bull market.  You have to live with the volatility and this is why he likes the ETF.  He would hold it long term.

E.T.F.'s
0 0 0 0 0
0 comments

(A Top Pick Nov. 17/17, Up 7%)  There was a three for one stock split.  This and healthcare are in a long term secular bull market.  You have to live with the volatility and this is why he likes the ETF.  He would hold it long term.

E.T.F.'s
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$110.090
Owned Owned
Yes

TOP PICK

It's in a long-term bull market and has beaten the S&P. Resistence in the high $120's. Biotech is good because unlike regular pharma stocks, you don't have to be worry about generic drugs to compete with you. Buying the ETF lowers volatility than individual stocks.

E.T.F.'s
0 0 0 0 0
0 comments

It's in a long-term bull market and has beaten the S&P. Resistence in the high $120's. Biotech is good because unlike regular pharma stocks, you don't have to be worry about generic drugs to compete with you. Buying the ETF lowers volatility than individual stocks.

E.T.F.'s
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$117.770
Owned Owned
Yes

PAST TOP PICK

(Past Top Pick on Sept 21, 2017, Up 6%) Has enjoyed a nice trend though it fell to $105 (in April) which is a test level. It's volatile, but every portfolio must hold biotech, which is what this ETF carries.

E.T.F.'s
0 0 0 0 0
0 comments

(Past Top Pick on Sept 21, 2017, Up 6%) Has enjoyed a nice trend though it fell to $105 (in April) which is a test level. It's volatile, but every portfolio must hold biotech, which is what this ETF carries.

E.T.F.'s
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$116.560
Owned Owned
Yes

PAST TOP PICK

(A Top Pick September 21 / 2017,  Up 1%) Still likes. Could have sold it earlier for a nice gain, but deep story on long-term basis, pricing issues that the industry’s going to have to deal with. If we can get above $120 with some volume, going to be really good. Great time to get into biotechs seasonally right now. Good place to be throughout the summer, but also on long-term basis. Still buying at these prices. 

E.T.F.'s
0 0 0 0 0
0 comments

(A Top Pick September 21 / 2017,  Up 1%) Still likes. Could have sold it earlier for a nice gain, but deep story on long-term basis, pricing issues that the industry’s going to have to deal with. If we can get above $120 with some volume, going to be really good. Great time to get into biotechs seasonally right now. Good place to be throughout the summer, but also on long-term basis. Still buying at these prices. 

E.T.F.'s
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$111.260
Owned Owned
Yes

TOP PICK

He believes in the biotech sector. It is a concept play considering aging population. ETF that allows you to participate in many companies that would require a lot of analysis.

E.T.F.'s
0 0 0 0 0
0 comments

He believes in the biotech sector. It is a concept play considering aging population. ETF that allows you to participate in many companies that would require a lot of analysis.

E.T.F.'s
0 0 0 0 0
0 comments
David Cockfield

Managing D, Northland Wealth Man...

Price Price
$112.140
Owned Owned
Yes

COMMENT

A very, very large ETF. You can take a look at the different ones. There is a great website ETF.COM where you could look at this, and it will show you some of its competitors. He thinks this is a good sector to be in.

E.T.F.'s
0 0 0 0 0
0 comments

A very, very large ETF. You can take a look at the different ones. There is a great website ETF.COM where you could look at this, and it will show you some of its competitors. He thinks this is a good sector to be in.

E.T.F.'s
0 0 0 0 0
0 comments
John Hood

President , J. C Hood Investment...

Price Price
$112.000
Owned Owned
Unknown

COMMENT

Sold Amgen (AMGN-Q) and bought this. Good move? He likes biotechs, but you need to recognize that it is a higher beta space and will be more volatile than other areas or other industries. There are some names in this he likes, but there are a couple that are not doing so well. He would rather pick and choose individual names, but that is going to create more risk because you are going to concentrate on 1 or 2 names. With IBB you get a more diversified risk. Thinks the space is going to do fine.

E.T.F.'s
0 0 0 0 0
0 comments

Sold Amgen (AMGN-Q) and bought this. Good move? He likes biotechs, but you need to recognize that it is a higher beta space and will be more volatile than other areas or other industries. There are some names in this he likes, but there are a couple that are not doing so well. He would rather pick and choose individual names, but that is going to create more risk because you are going to concentrate on 1 or 2 names. With IBB you get a more diversified risk. Thinks the space is going to do fine.

E.T.F.'s
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$104.050
Owned Owned
Unknown

TOP PICK

When looking at sector rotation, biotech technology to a certain degree, is sort of in the middle. The strong rotation we’ve seen has been in industrials, energy and financials, but healthcare is sort of in the middle. This is at a good level to step in. Not for the faint of heart.

E.T.F.'s
0 0 0 0 0
0 comments

When looking at sector rotation, biotech technology to a certain degree, is sort of in the middle. The strong rotation we’ve seen has been in industrials, energy and financials, but healthcare is sort of in the middle. This is at a good level to step in. Not for the faint of heart.

E.T.F.'s
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$311.210
Owned Owned
Yes

TOP PICK

This is a long-term theme. We are going to have a little bit of resistance at his initial target of $3.90. (Chart actually shows around $380. Did he misspeak? - Bill) There is some volatility with some pretty big swings.

E.T.F.'s
0 0 0 0 0
0 comments

This is a long-term theme. We are going to have a little bit of resistance at his initial target of $3.90. (Chart actually shows around $380. Did he misspeak? - Bill) There is some volatility with some pretty big swings.

E.T.F.'s
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$331.270
Owned Owned
Yes

COMMENT

He is very positive on the biotech sector. There had been a lot of negative news cycle during the election, so the sector consolidated for some time. He then got back in through this ETF in March. He just sold this, but only because of a portfolio rebalancing. A great way to play Biotech’s.

E.T.F.'s
0 0 0 0 0
0 comments

He is very positive on the biotech sector. There had been a lot of negative news cycle during the election, so the sector consolidated for some time. He then got back in through this ETF in March. He just sold this, but only because of a portfolio rebalancing. A great way to play Biotech’s.

E.T.F.'s
0 0 0 0 0
0 comments
Mike S. Newton,

Director &, Scotia Wealth Manage...

Price Price
$324.320
Owned Owned
No

PAST TOP PICK

(Top Pick Jun 28/17, Down 4.04%)  Season strength is June to September for Biotech.  It is the ramp up ahead of cold and flu season.  It broke a significance line and we are re-testing it.  Momentum has come out of the name in the last three weeks.  There is the continuous overhang of high drug prices in the US.  If it cannot hold $300 then get out of it.  It is no longer supported as a seasonal trade and he would get out of it.

E.T.F.'s
0 0 0 0 0
0 comments

(Top Pick Jun 28/17, Down 4.04%)  Season strength is June to September for Biotech.  It is the ramp up ahead of cold and flu season.  It broke a significance line and we are re-testing it.  Momentum has come out of the name in the last three weeks.  There is the continuous overhang of high drug prices in the US.  If it cannot hold $300 then get out of it.  It is no longer supported as a seasonal trade and he would get out of it.

E.T.F.'s
0 0 0 0 0
0 comments
Jon Vialoux

Research A, CastleMoore Inc....

Price Price
$304.060
Owned Owned
No

TOP PICK

The period of seasonal strength for biotech stocks is basically from mid-June to mid-September. The average gain for the NASDAQ Biotech technology index is about 8.17%, and has been positive 70% of the time since 1993. In this past week, it has broken out above the substantial trading range between $240 and $300. With the breakout, we can expect the magnitude of the range of about $60, to propel it to the upside by about $60, so the upside target is about $360.

E.T.F.'s
0 0 0 0 0
0 comments

The period of seasonal strength for biotech stocks is basically from mid-June to mid-September. The average gain for the NASDAQ Biotech technology index is about 8.17%, and has been positive 70% of the time since 1993. In this past week, it has broken out above the substantial trading range between $240 and $300. With the breakout, we can expect the magnitude of the range of about $60, to propel it to the upside by about $60, so the upside target is about $360.

E.T.F.'s
0 0 0 0 0
0 comments
Jon Vialoux

Research A, CastleMoore Inc....

Price Price
$316.880
Owned Owned
No

COMMENT

A good time to Short? The one biotech ETF that he is really familiar with is this one. Most of the Short story is already built-in, so he would be reluctant to Short. Some of the names in this are doing okay, but some are at all-time lows. He would be reluctant to Short this.

E.T.F.'s
0 0 0 0 0
0 comments

A good time to Short? The one biotech ETF that he is really familiar with is this one. Most of the Short story is already built-in, so he would be reluctant to Short. Some of the names in this are doing okay, but some are at all-time lows. He would be reluctant to Short this.

E.T.F.'s
0 0 0 0 0
0 comments
Mike S. Newton,

Director &, Scotia Wealth Manage...

Price Price
$284.300
Owned Owned
Unknown

Showing 1 to 15 of 57 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days